CD24蛋白与卵巢癌相关性的研究进展

Research progress on correlation between CD24 protein and ovarian cancer

卵巢癌为妇科肿瘤中的头号杀手,大部分患者早期缺乏明显症状及有效的筛查方法导致其发现较晚,预后不佳,卵巢癌患者5年生存率约为45%,中晚期患者多伴有腹水形成及化疗耐药性,这成为卵巢癌诊治中的一大难题。近年来,随着肿瘤靶向治疗领域的迅猛发展,提供给我们一种新的思路,是否可以通过免疫靶向治疗,更好的指导个体化治疗及改善卵巢癌患者的预后情况。分化簇(CDs)是不同细胞中的表面标志物,它们诱导细胞相互通讯的信号通路。最近在癌症研究中引起新兴趣的CD分子之一是CD24。CD24是一种小的重糖基化抗原,在多种癌症类型(包括卵巢癌)中过表达。CD24表达与癌细胞的发育、侵袭和转移有关。通过阅读大量文献,获悉CD24与卵巢癌发生发展及预后均有非常紧密的联系,下文将阐述CD24在卵巢癌方面的研究进展。

Ovarian cancer is the top killer in gynecological tumor.The lack of obvious symptoms and early screening methods lead to the late detection and poor prognosis.Five-year survival rate is about 45%.In middle-late patients,ascites formation and chemotherapy drug resistance are commonly seen.It becomes a big problem in the diagnosis and treatment of ovarian cancer.In recent years,with the rapid development of tumor targeted therapeutic area,whether the immune targeted therapy can better guide individualized treatment and improve the prognosis of patients with ovarian cancer.Differentiation clusters(CDs)are surface markers in different cells that induce signaling pathways for cells to communicate with each other.One of the CD molecules that has recently attracted new interest in cancer research is CD24.CD24 is a small,heavily glycosylated antigen that is overexpressed in many cancer types,including OC.CD24 expression is related to the development,invasion and metastasis of cancer cells.By reading a large number of literature,CD24 and ovarian cancer development and prognosis are very closely linked.This review will describe progress of CD24 in ovarian cancer.